A PK Study to Assess the Drug-drug Interaction of a BCRP Inhibitor on Adagrasib
Status:
COMPLETED
Trial end date:
2023-08-17
Target enrollment:
Participant gender:
Summary
A Phase 1, Open-label, One-sequence Crossover Study to Investigate the Effect of a Breast Cancer Resistance Protein Inhibitor on the Single-dose Pharmacokinetics of Adagrasib in Healthy Adult Subjects